Xtandi gets EU nod for use earlier in CRPC
This article was originally published in Scrip
Executive Summary
Astellas's prostate cancer therapy Xtandi (enzalutamide; licensed from Medivation) has been given the go-ahead for use earlier in the treatment paradigm by the EU's CHMP.